Literature DB >> 6328753

Tumorigenic activity of polyoma virus and SV40 DNAs in newborn rodents.

L Bouchard, C Gelinas, C Asselin, M Bastin.   

Abstract

A procedure has been developed whereby the oncogenicity of the DNA from polyoma (Py) virus and Simian virus 40 (SV40) can be tested directly by injecting recombinant DNA into newborn rodents. Injection of 0.2-2.0 micrograms of linear DNA induced the development of subcutaneous liposarcomas and fibrosarcomas at the site of inoculation. Coinjection of high-molecular-weight rat DNA as carrier had little or no effect on tumor formation but plasmids pBR322, pAT153 , and pML2 behaved as strong inhibitors. Tumor induction by injecting DNA into newborn rodents provides an in vivo equivalent to a transformation assay but appears to be a more stringent and rigorous criterion of oncogenic transformation. The oncogenic potential of Py virus in newborn hamsters could be expressed by a recombinant encoding only the middle T protein, although with average tumor latencies 5-10 times longer than those observed with wild-type Py DNA. Py middle T required the cooperation from small T to induce tumors in newborn rats. SV40 DNA was tumorigenic only in newborn hamsters. delta 2005 DNA which is unable to produce the SV40 small T antigen was much less active and required a latent period about twice that of wild-type SV40 DNA. However, its tumorigenic potential was restored by addition of the Py small T antigen gene. This indicates that Py and SV40 small T antigens are interchangeable and that they probably play an identical role in malignant transformation. Finally, evidence was provided that intermolecular recombination or recombination between DNA fragments can occur in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6328753     DOI: 10.1016/0042-6822(84)90116-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Acceptability of continuous cell lines for the production of biologicals.

Authors:  J Löwer
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

2.  Interactions between polyomavirus medium T antigen and three cellular proteins of 88, 61, and 37 kilodaltons.

Authors:  T Grussenmeyer; A Carbone-Wiley; K H Scheidtmann; G Walter
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Mutation in the polyomavirus genome that activates the properties of large T associated with neoplastic transformation.

Authors:  C Asselin; J Vass-Marengo; M Bastin
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

4.  Maintenance of an extrachromosomal plasmid vector in mouse embryonic stem cells.

Authors:  M Gassmann; G Donoho; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector.

Authors:  D Davidson; J A Hassell
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

6.  Resolution of a polyomavirus-mouse hybrid replicon: viral function required for recombination.

Authors:  A Piché; P Bourgaux
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

7.  Circular and linear simian virus 40 DNAs differ in recombination.

Authors:  D Dorsett; I Deichaite; E Winocour
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

8.  Analysis of a transgenic mouse containing simian virus 40 and v-myc sequences.

Authors:  J A Small; D G Blair; S D Showalter; G A Scangos
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

9.  Differential ability of a T-antigen transport-defective mutant of simian virus 40 to transform primary and established rodent cells.

Authors:  R E Lanford; C Wong; J S Butel
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

10.  Ability of a T-antigen transport-defective mutant of simian virus 40 to immortalize primary cells and to complement polyomavirus middle T in tumorigenesis.

Authors:  J Vass-Marengo; A Ratiarson; C Asselin; M Bastin
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.